Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia

18Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Autoimmunity is often observed among individuals with primary immune deficiencies; however, the frequency and role of autoimmunity in Schimke immuno-osseous dysplasia (SIOD) has not been fully assessed. SIOD, which is caused by mutations of SMARCAL1, is a rare autosomal recessive disease with its prominent features being skeletal dysplasia, T cell deficiency, and renal failure. We present a child with severe SIOD who developed rituximab resistant Evans syndrome (ES). Consistent with observations in several other immunodeficiency disorders, a review of SIOD patients showed that approximately a fifth of SIOD patients have some features of autoimmune disease. To our best knowledge this case represents the first patient with SIOD and rituximab resistant ES and the first study of autoimmune disease in SIOD. © 2011 Zieg et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Zieg, J., Krepelova, A., Baradaran-Heravi, A., Levtchenko, E., Guillén-Navarro, E., Balascakova, M., … Boerkoel, C. F. (2011). Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia. Pediatric Rheumatology, 9. https://doi.org/10.1186/1546-0096-9-27

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free